Treatment of retinal vein occlusion with macular edema

Article Sidebar

PDF (Język Polski)


Published: Jun 30, 2015
Keywords:
retinal vein occlusion, mocular edema, anti-VEGF therapy

Main Article Content

Ewa Piotrowska
Oddział Okulistyki, Szpital Czerniakowski w Warszawie
Agata Mikitiuk-Potyra
Oddział Okulistyki, Szpital Czerniakowski w Warszawie

Abstract


Retinal vein occlusion (RVO) and the resulting complications of diabetic maculopathy are the next most common vascular cause of impaired vision in the world. Management of RVO include identification and treatment of risk factors, diagnosis and treatment of vision impairment threatening complications. An important role in the treatment of macular edema in RVO play injections of anti-VEGF.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Piotrowska E, Mikitiuk-Potyra A. Treatment of retinal vein occlusion with macular edema. Ophthatherapy [Internet]. 2015Jun.30 [cited 2024May4];2(2):105-9. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/626
Issue
Vol 2 No 2 (2015)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Rogers S, McIntosh RL, Cheung N et al. The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117: 313-9.
2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996; 114: 1243-7.
3. Mirshahi A, Feltgen N, Hansen LL et al. Retinal vascular occlusions: an interdisciplinary challenge. Dtsch Arztebl Int. 2008; 105: 474-9.
4. Risk Factors for Central Retinal Vein Occlusion. The Eye Disorders Case-Control Study Group. Arch Ophthalmol. 1996; 114: 545-54.
5. Natural history and clinical management of central retinal vein occlusion. Central Retinal Vein Occlusion Study Group. Arch Ophthalmol. 1997; 115: 486-91.
6. NICE Interventional Procedure Guidance IPG334. Arteriovenous crossing sheathotomy for branch retinal vein occlusion. http://guidance.nice.org.uk/IPG334. (Access: 22.09.2010).
7. Brown DM, Campochiaro PA, Singh RP et al.; for CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology. 2010; 117: 1124-33.
8. Heier JS, Campochiaro PA, Yau L et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012; 119(4): 802-9.
9. Brown DM, Heier JS, Clark W; Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study Secondary to Central Retinal Vein Occlusion. Am J Ophthalmol. 2013; 155: 429-37.
10. Haller JA, Bandello F, Belfort R Jr et al.; OZURDEX GENEVA Study Group. Randomised, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010; 117: 1134-46.e3.
11. Shilling JS, Jones CA. Retinal branch vein occlusion: A study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol. 1984; 68: 196-8.
12. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: The Central Retinal Vein Occlusion Study Group N report. Ophthalmology. 1995; 102: 1434-44.